Telescope Innovations Presents Continued Growth in Fiscal Year 2024
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) reported financial results for fiscal year 2024, showing revenue growth of 57% to $4.4M from $2.8M in FY2023. The company posted an Adjusted EBITDA loss of $152K, improved from a $225K loss in FY2023. Expenses increased to $5.8M from $3.5M previous year.
Key achievements include launching a multi-year collaboration with Pfizer for self-driving labs development, securing a global distribution agreement with Mettler Toledo for DirectInject-LC™, and obtaining funding for a lithium refinement pilot plant. The company also advanced new IP in lithium sulfide production and battery recycling technologies.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) ha riportato i risultati finanziari per l'anno fiscale 2024, mostrando una crescita dei ricavi del 57% a $4,4M rispetto ai $2,8M dell'anno fiscale 2023. L'azienda ha registrato una perdita di EBITDA rettificato di $152K, in miglioramento rispetto a una perdita di $225K nell'anno fiscale 2023. Le spese sono aumentate a $5,8M dai $3,5M dell'anno precedente.
Tra i principali risultati si evidenzia il lancio di una collaborazione pluriennale con Pfizer per lo sviluppo di laboratori autonomi, l'ottenimento di un accordo di distribuzione globale con Mettler Toledo per DirectInject-LC™ e l'ottenimento di finanziamenti per un impianto pilota di raffinazione del litio. L'azienda ha anche fatto avanzamenti in nuove proprietà intellettuali nella produzione di solfuro di litio e nelle tecnologie di riciclaggio delle batterie.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) reportó los resultados financieros para el año fiscal 2024, mostrando un crecimiento de ingresos del 57% a $4.4M desde $2.8M en el año fiscal 2023. La compañía registró una pérdida de EBITDA ajustado de $152K, mejorando desde una pérdida de $225K en el año fiscal 2023. Los gastos aumentaron a $5.8M desde $3.5M el año anterior.
Logros clave incluyen el lanzamiento de una colaboración a varios años con Pfizer para el desarrollo de laboratorios autónomos, asegurar un acuerdo de distribución global con Mettler Toledo para DirectInject-LC™ y obtener financiamiento para una planta piloto de refinación de litio. La compañía también avanzó en nueva propiedad intelectual en la producción de sulfuros de litio y tecnologías de reciclaje de baterías.
텔레스코프 이노베이션스 코퍼레이션 (CSE: TELI) (OTCQB: TELIF)은 2024 회계연도의 재무 결과를 발표하며 57% 매출 성장을 이뤄 $4.4M을 기록했으며, 이는 2023 회계연도의 $2.8M에서 증가한 것입니다. 회사는 조정된 EBITDA 손실이 $152K로, 2023 회계연도의 $225K 손실에서 개선되었습니다. 비용은 이전 연도의 $3.5M에서 $5.8M으로 증가했습니다.
주요 성과로는 자율 실험실 개발을 위한 화이자와의 다년간 협업 출범, DirectInject-LC™에 대한 메틀러 토레도와의 글로벌 유통 계약 체결, 리튬 정제 파일럿 플랜트에 대한 자금 확보 등이 포함됩니다. 회사는 또한 리튬 황화물 생산 및 배터리 재활용 기술에 관한 새로운 지식재산권을 발전시켰습니다.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) a annoncé les résultats financiers pour l'exercice 2024, montrant une croissance des revenus de 57% à 4,4 millions de dollars contre 2,8 millions de dollars lors de l'exercice 2023. L'entreprise a enregistré une perte d'EBITDA ajusté de 152 000 dollars, améliorée par rapport à une perte de 225 000 dollars en 2023. Les dépenses ont augmenté à 5,8 millions de dollars contre 3,5 millions de dollars l'année précédente.
Les principaux succès incluent le lancement d'une collaboration pluriannuelle avec Pfizer pour le développement de laboratoires autonomes, la sécurisation d'un accord de distribution mondiale avec Mettler Toledo pour DirectInject-LC™, et l'obtention de financements pour une usine pilote de raffinage du lithium. L'entreprise a également fait progresser de nouvelles propriétés intellectuelles dans la production de sulfure de lithium et les technologies de recyclage des batteries.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) meldete die Finanzzahlen für das Geschäftsjahr 2024 und zeigte ein Umsatzwachstum von 57% auf 4,4 Millionen Dollar im Vergleich zu 2,8 Millionen Dollar im Geschäftsjahr 2023. Das Unternehmen verzeichnete einen angepassten EBITDA-Verlust von 152.000 Dollar, eine Verbesserung gegenüber einem Verlust von 225.000 Dollar im Geschäftsjahr 2023. Die Ausgaben stiegen von 3,5 Millionen Dollar im Vorjahr auf 5,8 Millionen Dollar.
Wichtige Erfolge umfassen den Start einer mehrjährigen Zusammenarbeit mit Pfizer zur Entwicklung von autonomen Laboren, den Abschluss eines globalen Vertriebsvertrags mit Mettler Toledo für DirectInject-LC™ sowie die Sicherstellung von Finanzmitteln für eine Lithiumraffinerie-Pilotanlage. Das Unternehmen hat auch neue IP in der Lithiumsulfidproduktion und in Technologien zur Batterierecycling vorangetrieben.
- Revenue growth of 57% year-over-year to $4.4M
- Reduced EBITDA loss from $225K to $152K
- Secured multi-year funded collaboration with Pfizer
- Established global distribution agreement with Mettler Toledo
- Obtained funding for lithium refinement pilot plant
- Expenses increased 66% to $5.8M from $3.5M
- Continued EBITDA losses of $152K
Increased revenues fueled major research and commercialization projects for intelligent automation products and advanced chemical manufacturing
Vancouver, British Columbia--(Newsfile Corp. - December 23, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal year ended August 31, 2024. The Company generated revenues of
Figure 1. Revenue and EBITDA for FY 23 and 24 in CAD, along with major milestones achieved in each fiscal year.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8923/234965_asset_25.jpg
FINANCIAL HIGHLIGHTS OF THE FISCAL YEAR ENDED AUGUST 31, 2024
All values are represented in CAD.
- Revenues of
$4.4 M , versus$2.8 M for FY 2023, representing57% revenue growth - Expenses of
$5.8 M , versus$3.5 M for FY 2023 - Adjusted EBITDA loss of
$152 K, versus loss of$225 K for FY 2023
"Our progress this year reflects the strategic focus and innovation driving Telescope forward," commented Henry Dubina, Telescope CEO. "By reinvesting in groundbreaking projects like our collaboration with Pfizer on self-driving labs, the global rollout of DirectInject-LC™ with Mettler Toledo, and our advancements in lithium refinement and recycling technologies, we are building a solid foundation for sustainable growth and long-term industry leadership."
Readers are encouraged to review the full financial statements and accompanying management discussion and analysis for the fiscal year ended August 31, 2024, both of which are available under the profile for the Company on SEDAR+ (www.sedarplus.ca).
About Telescope
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
On behalf of the Board,
Telescope Innovations Corp.
Henry Dubina, Chief Executive Officer
E: hdubina@telescopeinn.com
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234965
FAQ
What was Telescope Innovations (TELIF) revenue growth in FY 2024?
How much did TELIF's expenses increase in fiscal year 2024?
What major partnerships did Telescope Innovations secure in FY 2024?
What was TELIF's Adjusted EBITDA for fiscal year 2024?
What new technology developments did TELIF announce in FY 2024?
